RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재

      비스테로이드 소염제 사용 후 나타난 독성 표피 괴사 융해증 1례 = A Case of Toxic Epidermal Necrolysis (TEN) Induced by Nonsteroidal Anti- Inflammatory Drug (NSAID)

      한글로보기

      https://www.riss.kr/link?id=A104608973

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      A patient who was transferred to our Emergency Medical Center from a local clinic with a dermatologic disorder of unknown origin presented to us with TEN with a 40% skin slough. The patient was a 53-year-old women with complaints of erythematous rash ...

      A patient who was transferred to our Emergency Medical
      Center from a local clinic with a dermatologic disorder of
      unknown origin presented to us with TEN with a 40% skin
      slough. The patient was a 53-year-old women with complaints
      of erythematous rash and blisters on her trunk and
      both proximal extremities. She had taken NSAIDS, 1300 mg
      per oral, every 8 h for 5 days. Five days after administration
      of NSAIDS began, the doctors at the local clinic noted that a
      rash with blisters had begun on her back and progressed to
      her extremities. After 4 days of that progression she came to
      us. On physical examination, she had asymptomatic multiple
      clear filled bullae and erosion with brown- to black-colored
      hyperpigmentation on her trunk and proximal extremities
      involving 40% of the body surface. She was admitted to a
      private room to prevent secondary infections, and her management
      included fluid replacement, third-generation
      cephalosporin and corticosteroid administration, and intensive
      wound care. Fifteen days after admission, no further
      treatment was required, and only a small scar and a mild
      dispigmentation lesion could be seen.
      Emergency department physicians should think about TEN
      if the patient has extensive exfolating skin lesions.
      Treatment of patients with suspected TEN must be directed
      at minimizing fluid and electrolyte loss and preventing secondary
      infection, and an effort should be made to identify the
      suspicious drug and to educate patient to avoid the drug.

      더보기

      참고문헌 (Reference)

      1 Metry DW, "Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature" 112 : 1430-1436, 2003

      2 Quinn AM, "Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis" 141 : 683-687, 2005

      3 Abood GJ, "Treatment strategies in toxic epidermal necrolysis syndrome: where are we at" 29 : 269-276, 2008

      4 Brambilla G, "Treatment of toxic epidermal necrolysis (TEN)" 15 : 17-21, 2002

      5 Abe R, "Toxic epidermal necrolysis and Stevens- Johnson syndrome are induced by soluble Fas ligand" 162 : 1515-1520, 2003

      6 Garcia-Doval I, "Toxic epidermal necrolysis and Stevens- Johnson syndrome" 136 : 323-327, 2000

      7 Wolkenstein P, "Toxic epidermal necrolysis" 18 : 485-495, 2000

      8 Mockenhaupt M, "Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs" 128 : 35-44, 2008

      9 Ducic I, "Outcome of patients with toxic epidermal necrolysis syndrome revisited" 110 : 768-773, 2002

      10 Niebanck AE, "Neutropenia following IVIG therapy in pediatric patients with immune mediated thrombocytopenia" 27 : 145-147, 2005

      1 Metry DW, "Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature" 112 : 1430-1436, 2003

      2 Quinn AM, "Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis" 141 : 683-687, 2005

      3 Abood GJ, "Treatment strategies in toxic epidermal necrolysis syndrome: where are we at" 29 : 269-276, 2008

      4 Brambilla G, "Treatment of toxic epidermal necrolysis (TEN)" 15 : 17-21, 2002

      5 Abe R, "Toxic epidermal necrolysis and Stevens- Johnson syndrome are induced by soluble Fas ligand" 162 : 1515-1520, 2003

      6 Garcia-Doval I, "Toxic epidermal necrolysis and Stevens- Johnson syndrome" 136 : 323-327, 2000

      7 Wolkenstein P, "Toxic epidermal necrolysis" 18 : 485-495, 2000

      8 Mockenhaupt M, "Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs" 128 : 35-44, 2008

      9 Ducic I, "Outcome of patients with toxic epidermal necrolysis syndrome revisited" 110 : 768-773, 2002

      10 Niebanck AE, "Neutropenia following IVIG therapy in pediatric patients with immune mediated thrombocytopenia" 27 : 145-147, 2005

      11 Mukasa Y, "Management of toxic epidermal necrolysis and related syndromes" 84 : 60-65, 2008

      12 Wolf R, "Life-threatening acute adverse cutaneous drug reactions" 23 : 171-181, 2005

      13 Cuerda Galindo E, "Fixed drug eruption from piroxicam" 18 : 586-587, 2004

      14 Castana O, "Diseases mimicking a burn-outcome and treatment" 18 : 130-132, 2005

      15 Bachot N, "Differential diagnosis of severe cutaneous drug eruptions" 4 : 561-572, 2003

      16 Halevy S, "Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel" 58 : 25-32, 2008

      17 Lonjou C, "A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs" 18 : 99-107, 2008

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2027 평가예정 재인증평가 신청대상 (재인증)
      2021-01-01 평가 등재학술지 유지 (재인증) KCI등재
      2020-05-08 학회명변경 영문명 : The Korean Society Of Emergency Medicine -> The Korean Society of Emergency Medicine KCI등재
      2018-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2015-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2011-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2009-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2006-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2005-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2003-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.23 0.23 0.22
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.22 0.22 0.339 0.06
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼